Fiche publication
Date publication
avril 2026
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FUMET Jean-David
Tous les auteurs :
Fumet JD, Dugage MR, Danlos FX, Hueso T, Pinato DJ, Luke J, Bermejo IM, Lorusso P, Brody J, Harrington K, Segal NH, Diab A, Cabanas EG, Marron T, Houot R, Champiat S, Marabelle A
Lien Pubmed
Résumé
T-cell redirecting therapies, notably CAR T-cells and bispecific antibodies, have revolutionized the treatment of hematologic malignancies. Their rapid expansion into solid tumors, alongside the emergence of next-generation agents, such as immunocytokines and CD28-costimulatory bispecifics, has brought Cytokine Release Syndrome (CRS) to the forefront of clinical oncology. However, the absence of a unified grading system for these novel constructs remains a critical barrier to drug development and patient safety. Current toxicity management relies on disparate grading scales leading to inconsistent reporting and hindering cross-trial comparisons. A fundamental challenge lies in the diagnostic ambiguity created by the significant clinical and temporal overlap between CRS, infusion-related reactions (IRRs), and other diagnosis. While fever, hypotension, and hypoxia are common denominators, their distinct pathophysiological drivers necessitate divergent therapeutic interventions.
Mots clés
Adverse event reporting, CAR-T cell therapy, Clinical trial safety, Cytokine Release Syndrome (CRS), Immunotherapy, T-cell engaging therapy
Référence
Ann Oncol. 2026 04 1;:
